[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) Form 144 notifies a proposed sale of 11,411 common shares through Merrill Lynch with an aggregate market value of $234,656.73, scheduled approximately for 09/05/2025 on NASDAQ. The filing shows the shares were acquired the same day as a stock option exercise and paid in cash. The filer (person for whose account the shares will be sold) recorded prior open-market dispositions in the past three months totaling 23,844 shares for gross proceeds of $420,084.80 on 06/02/2025, 08/19/2025 and 09/04/2025. The notice includes the required signature representation about absence of undisclosed material information.

Positive

• Full disclosure of proposed sale details: broker, share count, market value, exchange and sale date are provided
• Acquisition method is explicit: shares were acquired via a stock option and paid in cash on the acquisition date
• Historical sales disclosed: prior three months of dispositions (dates, amounts, proceeds) are itemized, improving transparency

Negative

• Insider selling activity: the filer sold 23,844 shares in the past three months for aggregate gross proceeds of $420,084.80
• Concentrated upcoming sale: proposed sale of 11,411 shares represents a material single transaction relative to the disclosed outstanding shares (43,470,125)

Insights

Securities Analyst

TL;DR: Insider sale notice: 11,411 shares to be sold; prior three-month sales totaled 23,844 shares for $420,084.80.

The filing documents a routine Rule 144 notice for the sale of shares acquired via stock option exercise on the same date, with proceeds to be received in cash through Merrill Lynch. The detailed history of disposals in the last three months provides transparency on recent insider liquidity. There is no forward-looking financial data or company performance metrics in this filing to assess broader financial impact.

Corporate Governance Expert

TL;DR: Governance disclosure is complete for a Rule 144 sale; shows significant insider selling activity over recent months.

The Form 144 fulfills regulatory disclosure requirements by listing broker, share count, acquisition method (stock option), and recent sale history. Repeated sales by the same person within three months may warrant attention from governance and compliance teams but the form itself contains no statements about company operations or undisclosed material events. The representation regarding absence of undisclosed material information is included as required.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	11411	234656.73	43470125	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Stock Option	Issuer			11411	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Hopman 11 HUGHES Irvine CA 92618	Common	09/04/2025	6818	136179.70
Mark Hopman 11 HUGHES Irvine CA 92618	Common	08/19/2025	16158	268376.10
Mark Hopman 11 HUGHES Irvine CA 92618	Common	06/02/2025	868	15529.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Beta Bionics (BBNX) file Form 144 for?

The filing notifies a proposed sale under Rule 144 of 11,411 common shares through Merrill Lynch with an aggregate market value of $234,656.73.

When is the planned sale of BBNX shares scheduled?

The Form 144 lists an approximate sale date of 09/05/2025 on the NASDAQ exchange.

How were the shares being sold acquired according to the filing?

The shares were acquired on 09/05/2025 via a stock option from the issuer and payment was in cash.

Has the filer sold BBNX shares recently?

Yes. The filer sold 6,818 shares on 09/04/2025, 16,158 shares on 08/19/2025, and 868 shares on 06/02/2025, totaling 23,844 shares for $420,084.80.

Which broker is handling the proposed sale?

The broker named in the filing is Merrill Lynch, address listed in Rancho Santa Fe, CA.

Does the filing state there is any undisclosed material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.